The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Whole genomes redefine the mutational landscape of pancreatic cancer
Open accessAbstract
Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We performed whole-genome sequencing and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinomas (PDACs). Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2) and new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2). Patterns of structural variation (variation in chromosomal structure) classified PDACs into 4 subtypes with potential clinical utility: the subtypes were termed stable, locally rearranged, scattered and unstable. A significant proportion harboured focal amplifications, many of which contained druggable oncogenes (ERBB2, MET, FGFR1, CDK6, PIK3R3 and PIK3CA), but at low individual patient prevalence. Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency. Of 8 patients who received platinum therapy, 4 of 5 individuals with these measures of defective DNA maintenance responded.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“supporting previous studies linking loss of PALB2 function with BRCA-deficient signatures [7, 10, 13].”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [10]
In the citing paper
“Loss of function of BRCA1, BRCA2 and PALB2 yield a high mutation burden and specific signatures inferring defective HR [7, 9, 10, 13].”
From Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers (2019) · cites this paper as [10]
In the citing paper
“G12V is frequently identified in pancreatic ductal adenocarcinomas and is associated with aggressive disease biology [16,21].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [21]
In the citing paper
“Chromatin remodeling and SWI/SNF complex genes are one of the most frequently altered class of genes in PDAC45,48–50, and can occur via somatic deletions of the associated chromosomal loci94.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [49]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Circos: An information aesthetic for comparative genomicsPreprint
Krzywinski, M. I., Schein, J. E., Birol, İ., Connors, J. M., Gascoyne, R. D., Horsman, D. E., Jones, S. J. M., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 11,073
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationIntegrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 1×
“The majority of structural variants were intra-chromosomal (10,114) and were classified into 7 types: intra-chromosomal rearrangements (5,860), deletions (1,393), duplications (128), tandem duplications (179), inversions (1,629), foldback inversions (579) and amplified inversions (346); inter-chromosomal translocation…”
BackgroundMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,006
Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment
Porazinski, S. R., Parkin, A., & Pajic, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35582-1_6 · Cited by 34
Self-citationKryza, T., Khan, T., Puttick, S. G., Li, C., Sokolowski, K. A., Tse, B. W.-C., Cuda, T., Lyons, N., Gough, M., Yin, J. X. M., et al. (2020) · Theranostics · doi:10.7150/thno.43589 · Cited by 31
“Human samples used in this study were in compliance with ethical approval obtained by the Australian Pancreatic Cancer Genome Initiative International Cancer Genome Consortium [33-35].”
BackgroundMethodSelf-citationMetabolic therapy and bioenergetic analysis: The missing piece of the puzzle
Duraj, T., Carrión-Navarro, J., Seyfried, T. N., Garcia‐Romero, N., & Ayuso‐Sacido, Á. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101389 · Cited by 36
“In the same way, pancreatic cancer is an appealing target for metabolic intervention due to speci fi c metabolic subtypes, KRAS governance, mitochondrial defects, and generally poor prognosis [171,172].”
Moving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34
Rabenau, K. E., & Hofstatter, E. W. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.006 · Cited by 34
Pellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10058-y · Cited by 33
Masuda, S., Koizumi, K., Shionoya, K., Jinushi, R., Makazu, M., Nishino, T., Kimura, K. A., Sumida, C., Kubota, J., Ichita, C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1863 · Cited by 33
Pancreatic cancer: BRCA mutation and personalized treatment
Luo, G., Yu, L., Jin, K., He, C., Guo, M., Liu, Z., Long, J., Liu, C., Ni, Q., & Yu, X. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1086271 · Cited by 34
“Whole exome sequencing (WES) and, importantly, whole genome sequencing (WGS) will provide more information on the potential deficiencies in DNA damage repair and identify potential therapeutic targets to platinum and PARPi [68].”
BackgroundInfluentialMultimodal treatment of resectable pancreatic ductal adenocarcinoma
Silvestris, N., Brunetti, O., Vasile, E., Cellini, F., Cataldo, I., Pusceddu, V., Cattaneo, M., Partelli, S., Scartozzi, M., Aprile, G., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.015 · Cited by 32
Self-citationWhat treatment in 2017 for inoperable pancreatic cancers?
Taı̈eb, J., Pointet, A., Laethem, J. V., Laquente, B., Pernot, S., Lordick, F., & Reni, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx174 · Cited by 33
Wald, P., Liu, X. S., Pettit, C. J., Dillhoff, M. E., Manilchuk, A., Schmidt, C. R., Wuthrick, E. J., Chen, W., & Williams, T. M. (2017) · Oncotarget · doi:10.18632/oncotarget.20277 · Cited by 33
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 32
“Using data from whole-genome sequencing, Waddell and colleagues identified four different PC subtypes [36].”
MethodSelf-citationTozzi, M., Sørensen, C. E., Magni, L., Christensen, N. M., Bouazzi, R., Buch, C. M., Stefanini, M., Duranti, C., Arcangeli, A., & Novak, I. (2020) · Cancers · doi:10.3390/cancers12030640 · Cited by 33
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms
Al‐Toubah, T., Cives, M., & Strosberg, J. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.12.18 · Cited by 33
“Tumor mutational burden is relatively low, and microsatellite instability is extremely rare (4,5).”
BackgroundSmith, S. J., Li, C. M., Lingeman, R. G., Hickey, R. J., Liu, Y., Malkas, L. H., & Raoof, M. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.025 · Cited by 33
Wan, X., Guo, D., Zhu, Q., & Qu, R. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00322.2019 · Cited by 33
Golob-Schwarzl, N., Puchas, P., Gogg-Kamerer, M., Weichert, W., Göppert, B., & Haybaeck, J. (2020) · Anticancer Research · doi:10.21873/anticanres.14292 · Cited by 27
Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Čierniková, S., Earl, J., García‐Bermejo, L., Števurková, V., Carrato, A., & Smolková, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114091 · Cited by 36
The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma
Tsuda, M., Fukuda, A., Kawai, M., Araki, O., & Seno, H. (2020) · Cancer Science · doi:10.1111/cas.14768 · Cited by 36
“Uehara Foundation, Grant/Award Number: 201720143; Takeda Foundation, Grant/ Award Number: 201749741; Mochida Foundation, Grant/Award Number: 2017bvAg; Mitsubishi Foundation, Grant/ Award Number: 201910037; Princess Takamatsu Cancer Research Fund, Grant/ Award Number: 17-24924; Grants-inAid KAKENHI, Grant/Award Number:…”
ResultYao, H.-J., Song, W., Cao, R., Ye, C., Zhang, L., Chen, H., Wang, J., Shi, Y., Li, R. P., Li, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33037-x · Cited by 34
Genomic heterogeneity in pancreatic cancer organoids and its stability with culture
Usman, O. H., Zhang, L., Xie, G., Kocher, H. M., Hwang, C., Wang, Y. J., Mallory, X., & Irianto, J. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00342-9 · Cited by 36
“This pattern is in line with the typical signatures of chromothripsis, as reported in numerous cancers, including PDAC 24,25 .”
Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic
Borecká, M., Zemánková, P., Vočka, M., Souček, P., Soukupová, J., Kleiblová, P., Sevcik, J., Kleibl, Z., & Janatová, M. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.03.003 · Cited by 33
Identification of coding and non-coding mutational hotspots in cancer genomes
Piraino, S. W., & Furney, S. J. (2017) · BMC Genomics · doi:10.1186/s12864-016-3420-9 · Cited by 32
Golan, T., Stossel, C., Schvimer, M., Atias, D., Halperin, S., Buzhor, E., Raitses‐Gurevich, M., Cohen, K., Pri‐Chen, S., Wilson, J. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17253 · Cited by 33
“One subtype (unstable genome) is enriched with tumors demonstrating DNA damage repair deficiency (DDR subtype) [5].”
BackgroundInfluentialShen, C., Yan, T., Liu, W. C., Zhu, X., Tian, X., Fu, X., Hua, R., Zhang, J., Huo, Y., Liu, D., et al. (2017) · Journal of Cancer · doi:10.7150/jca.20086 · Cited by 33
“Pancreatic ductal adenocarcinoma is one of the most malignant cancers worldwide with increasing morbidity and mortality [18-20].”
BackgroundAkt and SGK protein kinases are required for efficient feeding by macropinocytosis
Williams, T. D., Peak‐Chew, S., Paschke, P., & Kay, R. R. (2019) · Journal of Cell Science · doi:10.1242/jcs.224998 · Cited by 30
“Ras proteins are especially frequently mutated with, strikingly, ∼95% of pancreatic cancers driven by K-Ras (Fernandez-Medarde and Santos, 2011; Kandoth et al., 2013; Prior et al., 2012; Waddell et al., 2015).”
BackgroundReplication Study: Melanoma genome sequencing reveals frequent PREX2 mutations
Horrigan, S. K., Courville, P., Sampey, D. B., zhou, F., Cai, S., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.21634 · Cited by 32
“*For correspondence: tim@cos.io; nicole@scienceexchange.com”
ResultWang, S., Xiong, Y., Luo, Y., Shen, Y., Zhang, F., Lan, H., Pang, Y., Wang, X., Li, X., Zheng, X., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00060-y · Cited by 32
“The genomic landscape of PDAC has provided a rich source of therapeutic target identi fi cation (Network, 2017; Waddell et al, 2015).”
Striefler, J. K., Sinn, M., Pelzer, U., Jühling, A., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Dörken, B., Oettle, H., et al. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.001 · Cited by 31
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
Renouf, D. J., Hedley, D. W., Krzyzanowska, M. K., Schmuck, M., Wang, L., & Moore, M. J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3102-y · Cited by 32
Kipps, E., Young, K., & Starling, N. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016688816 · Cited by 32
“2014], there are also a multitude of infrequently mutated genes in pancreatic cancer [Waddell et al. 2015] and the majority of the trials to date have been in unselected populations.”
BackgroundConway, J. R. W., Vennin, C., Cazet, A., Herrmann, D., Murphy, K. J., Warren, S. C., Wullkopf, L., Boulghourjian, A., Zaratzian, A., Silva, A. M. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17177-5 · Cited by 32
Self-citationShibata, W., Kinoshita, H., Hikiba, Y., Sato, T. A., Ishii, Y., Sue, S., Sugimori, M., Suzuki, N., Sakitani, K., Ijichi, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24375-2 · Cited by 33
Nahm, C. B., Turchini, J., Jamieson, N. B., Moon, E. A., Sioson, L., Itchins, M., Arena, J., Colvin, E. K., Howell, V. M., Pavlakis, N., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.10.050 · Cited by 32
Self-citationThe role of metabolic adaptation to nutrient stress in pancreatic cancer
Derle, A., Santis, M. C. D., Gozzelino, L., Ratto, E., & Martini, M. (2018) · Cell Stress · doi:10.15698/cst2018.12.166 · Cited by 33
“tion, other oncogenes and tumor suppressors, such as SMAD, Myc and p53, regulate the cellular metabolic state and are frequently mutated in PDAC [2, 9, 11, 12].”
BackgroundPancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease
Gromisch, C. M., Qadan, M., Machado, M. A., Liu, K., Colson, Y. L., & Grinstaff, M. W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2731 · Cited by 32
Malignant epithelial/exocrine tumors of the pancreas
Luchini, C., Grillo, F., Fassan, M., Vanoli, A., Capelli, P., Paolino, G., Ingravallo, G., Renzulli, G., Doglioni, C., D’Amuri, A., et al. (2020) · Pathologica · doi:10.32074/1591-951x-167 · Cited by 32
Self-citationAdjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
Pappalardo, A., Giunta, E. F., Tirino, G., Pompella, L., Federico, P., Daniele, B., Vita, F. D., & Petrillo, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695627 · Cited by 32
“In 2015, the consortium led by Biankin and Grimmond identified a small percentage of PDAC (< 15%) with high genomic instability due to serious defects in DNA integrity maintenance (creating the so called “BRCA signature”) (102).”
BackgroundChallenges and Future Perspectives of Immunotherapy in Pancreatic Cancer
Wandmacher, A. M., Letsch, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13164235 · Cited by 33
Xiao, M., Liang, X.-J., Yan, Z., Chen, J., Zhu, Y., Xie, Y., Li, Y., Li, X., Gao, Q., Feng, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.803962 · Cited by 33
“Transcriptomic, DNAm and clinical data of ICGC-PACA-AU (15) and ICGC-PACA-CA (16) projects were obtained from the ICGC database.”
MethodInfluentialSeeber, A., Battaglin, F., Zimmer, K., Kocher, F., Baca, Y., Xiu, J., Spizzo, G., Novotny‐Diermayr, V., Rieder, D., Puccini, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3018 · Cited by 31
Bioinformatics roadmap for therapy selection in cancer genomics
Jiménez‐Santos, M. J., García‐Martín, S., Torre, C. F., Domenico, T. D., Goméz-López, G., & Al‐Shahrour, F. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13286 · Cited by 35
Han, Y., Drobisch, P., Krüger, A., William, D., Grützmann, K., Böthig, L., Polster, H., Seifert, L., Seifert, A. M., Distler, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01404-w · Cited by 34
Self-citationHereditary colorectal, gastric, and pancreatic cancer: comprehensive review
Seppälä, T. T., Burkhart, R. A., & Katona, B. W. (2023) · BJS Open · doi:10.1093/bjsopen/zrad023 · Cited by 36
d’Engremont, C., Vernerey, D., Pointet, A., Simone, G., Fein, F., Heyd, B., Koch, S., Vuitton, L., Kim, S. C. H., Jary, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2860-6 · Cited by 33
“However, these conventional clinical parameters as well as gene mutation status are insufficient to predict accurately deathrisk and the probability of long-term remission [7, 8].”
BackgroundMolecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic
Du, Y., Zhao, B., Liu, Z., Ren, X., Zhao, W., Li, Z., You, L., & Zhao, Y. (2017) · Journal of Cancer · doi:10.7150/jca.17622 · Cited by 32
“[20] performed CNV analysis of 100 PDACs and observed a high prevalence of chromosomal rearrangements involving genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2), as well as new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2).”
BackgroundInfluentialSaiyin, H., Na, N., Han, X., Fang, Y., Wu, Y., Lou, W., & Yang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17965 · Cited by 35
“As TSC2 mutation in PDAC is rare [3, 29], it is likely that BRSK2 downregulates mTORC1 through phosphorylation of TSC2.”
BackgroundProteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer
Ger, M., Kaupinis, A., Petrulionis, M., Kurlinkus, B., Cicenas, J., Šileikis, A., Valius, M., & Strupas, K. (2018) · Anticancer Research · doi:10.21873/anticanres.12914 · Cited by 32
Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer
Carnevale, J. C., & Ashworth, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6961 · Cited by 32
Ahmed, A., Greenhalf, W., Palmer, D., Williams, N., Worthington, J., Arshad, T., Haider, S., Alexandrou, E., Guneri, D., Waller, Z., et al. (2023) · Molecules · doi:10.3390/molecules28062452 · Cited by 22
Yang, S., Kuo, T., Wu, H., Guo, J., Hsu, C., Hsu, C., Tien, Y., Yeh, K., Cheng, A., & Kuo, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7275 · Cited by 33
Dieter, S. M., Giessler, K. M., Kriegsmann, M., Dubash, T. D., Möhrmann, L., Schulz, E. R., Siegl, C., Weber, S., Strakerjahn, H., Oberlack, A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30561 · Cited by 31
“Within the last years, comprehensive molecular characterization of individual tumors has uncovered landscapes of genomic diversity across multiple cancers.(1,2) Genetic and functional cancer cell heterogeneity are poorly reflected in both standard tumor cell lines that are expanded in vitro for years to decades, and i…”
BackgroundYan, J., Yu, S., Jia, C., Li, M., & Chen, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188367 · Cited by 33
Ahmed, A. A., Marchetti, C., Ohnmacht, S. A., & Neidle, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-68944-w · Cited by 32
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 33
Roger, É., Gout, J., Arnold, F., Beutel, A. K., Müller, M., Abaei, A., Barth, T. F. E., Rasche, V., Seufferlein, T. T. W., Perkhofer, L., et al. (2020) · Cells · doi:10.3390/cells9092110 · Cited by 31
“The POLO trial provided a milestone in targeted therapy of PDAC albeit tailored to a minimal subgroup of around 3–6% of germline BRCA1/2-mutated patients with pancreatic cancer [7,29].”
BackgroundCircadian Genes as Therapeutic Targets in Pancreatic Cancer
García-Costela, M., Escudero-Feliú, J., Puentes-Pardo, J. D., Moreno-SanJuan, S., Morales, S., Ríos‐Arrabal, S., Carazo, Á., & León, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00638 · Cited by 32
Emelyanova, M., Pudova, E. A., Khomich, D., Krasnov, G. S., As, P., Abramov, I. S., Mikhailovich, V. M., Филипенко, М. Л., Menshikova, S., Tjulandin, S. A., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083050 · Cited by 31
Bao, C., Tourdot, R. W., Brunette, G. J., Stewart, C., Sun, L., Baba, H., Watanabe, M., Agoston, A. T., Jajoo, K., Davison, J. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41805-6 · Cited by 42
“3-state (10) >3 state (17) amp (13) subclonal (2)”
Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin
Reichert, M., Blume, K., Kleger, A., Hartmann, D., & von Figura, G. (2015) · Stem Cells International · doi:10.1155/2016/9298535 · Cited by 35
“As controversial as this theory might be, it is one way to explain tumor heterogeneity, and solid tumors, especially pancreatic ductal adenocarcinomas (PDA), are heterogeneous [2, 3].”
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Khouzam, R. A., Lehn, J., Mayr, H., Clavien, P., Wallace, M. B., Ducreux, M. P., Limani, P., & Chouaïb, S. (2023) · Cancers · doi:10.3390/cancers15041235 · Cited by 33
“This included an “unstable” subtype, which harbors greater than 200 variants [17], and was found to be associated with the HRD signature.”
BackgroundPancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
Mosalem, O. M., Abdelhakeem, A. A. F., Abdel-Razeq, N. H., & Babiker, H. M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473698 · Cited by 33
“SMAD4 , a regulator of the TGF-β signaling pathway, is also mutated in approximately 50% of PDAC cases, can disrupt the tumor suppressive functions of TGF-β , promoting tumor growth and contributing to the dense, fibrotic stroma characteristic of PDAC [9,10].”
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Verdaguer, H., Saurí, T., & Macarulla, T. M. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.15 · Cited by 32
“In a study published by Waddell and colleagues (55), whole-genome sequencing and copy number variation analysis of 100 pancreatic ductal adenocarcinomas was performed.”
BackgroundLin, M., Alnaggar, M., Liang, S., Chen, J., Xu, K., Dong, S., Du, D., & Niu, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490874 · Cited by 32
Multi-omic molecular comparison of primary versus metastatic pancreatic tumours
Brar, G. S., Blais, E. M., Bender, R. J., Brody, J. R., Sohal, D. P. S., Madhavan, S., Picozzi, V. J., Hendifar, A. E., Chung, V. M., Halverson, D., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0507-5 · Cited by 30
Yan, W., Liu, X., Wang, Y., Han, S., Wang, F., Liu, X., Xiao, F., & Hu, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00534 · Cited by 30
“Until now, most of research effort in PDAC has been directed at identifying the important disease-driving genes and pathways (Waddell et al., 2015).”
BackgroundWang, Y., Park, J. Y. P., Pacis, A., Denroche, R. E., Jang, G. H., Zhang, A. X. W., Cuggia, A., Domecq, C., Monlong, J., Raitses‐Gurevich, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1439 · Cited by 29
Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer
Sharbeen, G. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00010 · Cited by 30
“On this point, recent data from the Australian Pancreatic Genome Initiative showed that 14% of pancreatic cancers display high genomic instability and a further 36% display substantial “scattered” genomic instability (141).”
BackgroundAlterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications
Silverman, B., & Shi, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122138 · Cited by 32
“e t st fre e tl altere ist e et lati re lat r e es i a creatic ca cer are 6 a LL2 [1].”
BackgroundInfluentialObazee, O. M., Archibugi, L., Andriulli, A., Souček, P., Malecka-Panas, E. I., Ivanauskas, A., Johnson, T., Gazouli, M., Pausch, T. M., Lawlor, R. T., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32127 · Cited by 29
“J. Cancer: 145, 686–693 (2019) © 2019 UICC C an ce r G en et ic s an d E pi ge n et ic s and BRCA2.”
BackgroundSelf-citationConcentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma
Gómez‐Tomás, Á., Pumarega, J. A., Alguacil, J., Amaral, A. F. S., Malats, N., Pallarés, N., Gasull, M., Porta, M. S., & for the PANKRAS II Study Group (2019) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22296 · Cited by 30
“In PDAC, codon 12 mutations are identified in 70–90% of tumors (Deramaudt and Rustgi, 2005; Porta et al. 1999a; Waddell et al. 2015).”
BackgroundMCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma
(APGI), A. P. C. G. I., Castillo, L. E., Young, A. I. J., Mawson, A., Schafranek, P., Steinmann, A. M., Nessem, D., Parkin, A., Johns, A. L., Chou, A. S. Y., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1091-0 · Cited by 29
Self-citationImmune-related somatic mutation genes are enriched in PDACs with diabetes
Wang, K., Zhou, W., Meng, P., Wang, P., Zhou, C., Yao, Y., Wu, S., Wang, Y., Zhao, J., Zou, D., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.03.006 · Cited by 29
The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers
Matsuoka, T., & Yashiro, M. (2023) · Biomolecules · doi:10.3390/biom13101551 · Cited by 32
“Approximately 40% of genetic alterations in mediators of TGF-β signaling occur in gastrointestinal (GI) cancers [2–4].”
BackgroundXiang, J.-F., Wang, W.-Q., Liu, L., Xu, H., Wu, C., Yang, J., Qi, Z.-H., Wang, Y.-Q., Xu, J., Liu, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19222 · Cited by 31
RetractedThe possibility of clinical sequencing in the management of cancer
Kou, T., Kanai, M., Matsumoto, S., Okuno, Y., & Muto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw018 · Cited by 30
PALB2: research reaching to clinical outcomes for women with breast cancer
Southey, M. C., Winship, I., & Nguyen‐Dumont, T. (2016) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-016-0049-2 · Cited by 29
“deficiency in pancreatic cancers that could benefit from platinum therapies [33].”
BackgroundMollinedo, F., & Gajate, C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.06.40 · Cited by 29
“Additional frequently mutated genes also include TP53, SMAD4, CDKN2A, ARID1A, ROBO2, PREX2, BRCA2 and MLL3 (25,28).”
BackgroundPalacio, S., McMurry, H. S., Ali, R. A., Donenberg, T. R., Silva‐Smith, R., Wideroff, G. A., Sussman, D. A., Lima, C. M. S. R., & Hosein, P. J. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.09.12 · Cited by 29
“Patients with pathogenic variants in DNA damage repair (DDR) genes may derive greater benefit with platinum-based chemotherapy in metastatic PDAC (8,9).”
BackgroundInfluentialATM Serine/Threonine Kinase and its Role in Pancreatic Risk
Nanda, N., & Roberts, N. J. (2020) · Genes · doi:10.3390/genes11010108 · Cited by 30
“In addition, a mutation spectrum associated with BRCA1/BRCA2-deficient cancers, including PDAC, was defined [46,58,59].”
BackgroundApplication of liquid biopsy for surgical management of pancreatic cancer
Nagai, M., Sho, M., Akahori, T., Nakagawa, K., & Nakamura, K. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12317 · Cited by 29
Yokose, T., Kitago, M., Matsuda, S., Sasaki, Y., Masugi, Y., Nakamura, Y., Shinoda, M., Yagi, H., Abe, Y., Oshima, G., et al. (2020) · Cancer Science · doi:10.1111/cas.14425 · Cited by 28
“Preoperative CA19-9, IU/mL; median (range) 100 (1-2392)”
Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer
Jugniot, N., Bam, R., Meuillet, E. J., Unger, E. C., & Paulmurugan, R. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10183 · Cited by 26
Current methods in translational cancer research
Lee, M. W., Miljanic, M., Triplett, T., Ramírez, C., Aung, K. L., Eckhardt, S., & Capasso, A. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09931-5 · Cited by 32
Zhu, L., Wu, Z., Li, R., Xing, X., Jiang, Y., Li, J., Wang, Y., Hu, L.-P., Wang, X., Qin, W., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.49243 · Cited by 29
“key oncogenes and tumor suppressor genes, including KRAS, TP53, CDKN2A, and SMAD4 [2, 3].”
BackgroundInfluentialPeretti, U., Cavaliere, A., Niger, M., Tortora, G., Marco, M. D., Rodriquenz, M. G., Centonze, F., Rapposelli, I. G., Giordano, G., Vita, F. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100032 · Cited by 29
“Number 939 820 76 43 Gender Male, n (%) 492 (52) 431 (53) 40 (53) 21 (49) Female, n (%) 447 (48) 389 (47) 36 (47) 22 (51) Age, n (%) Median 62 62 59 64 Range 28-87 28-87 33-73 45-78 <41 35 (4) 29 (4) 6 (8) 0 41-50 115 (12) 100 (12) 12 (16) 3 (7) 51-60 282 (30) 243 (30) 26 (34) 13 (30) 61-70 327 (35) 287 (35) 22 (29) 1…”
Self-citationAdvances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29
Tarasiuk, A., Mackiewicz, T., Malecka-Panas, E. I., & Fichna, J. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1941584 · Cited by 29
Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31
Diehl, J. N., Klomp, J. E., Snare, K. R., Hibshman, P. S., Blake, D. R., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101335 · Cited by 30
Racu, M.-L., Lebrun, L., Schiavo, A. A., Campenhout, C. V., Clercq, S. D., Absil, L., Minguijón, E., Maris, C., Decaestecker, C., Salmon, I. J., et al. (2022) · Cancers · doi:10.3390/cancers14040973 · Cited by 31
Subtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 32
Targeting autophagy as a therapeutic strategy against pancreatic cancer
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01889-1 · Cited by 29
“However, unlike other types of cancer, mutations in MHC-I are rare in PDAC [99].”
BackgroundSiret, C., Dobric, A., Մարտիրոսյան, Ա., Terciolo, C., Germain, S., Bonier, R., Dirami, T., Dusetti, N., Tomasini, R., Rubis, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.411 · Cited by 29
“In addition to these commonly recognised genetic drivers of pancreatic carcinogenesis, a recent genomic analysis of PDAC has increased the number of genomic alterations (Waddell et al, 2015; Bailey et al, 2016).”
BackgroundA look at the progress of treating pancreatic cancer over the past 20 years
Göß, R., & Frieß, H. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1428093 · Cited by 30
Hopkins, J. F., Denroche, R. E., Aguiar, J. A., Notta, F., Connor, A. A., Wilson, J. M., Stein, L. D., Gallinger, S., & Boutros, P. C. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.029 · Cited by 30
Alver, T. N., Bergholtz, H., Holm, M. B., Dorg, L. T., Skrede, M. L., Kure, E. H., & Verbeke, C. S. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100726 · Cited by 28
Sannino, G., Armbruster, N. S., Bodenhöfer, M., Haerle, U., Behrens, D., Buchholz, M., Rothbauer, U., Sipos, B., & Schmees, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12455 · Cited by 28
“Global genomic analyses revealed that, in the prevalence of PDAC cases, the WNT pathway is one of the most strongly altered signaling pathways [16, 17].”
BackgroundAu, T. H., Wang, K., Stenehjem, D. D., & Garrido‐Laguna, I. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.04 · Cited by 29
“Most PDAC patients present with advanced disease, and therefore they are not candidates for surgical resection.”
BackgroundInfluentialThe CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells
Barnett, D., Liu, Y., Partyka, K. A., Huang, Y., Tang, H., Hostetter, G. H., Brand, R. E., Singhi, A. D., Drake, R. R., & Haab, B. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-04164-z · Cited by 28
Metadata
- Authors
- Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., Quek, K., Quinn, M. C. J., Robertson, A. J., Fadlullah, M. Z. H., Bruxner, T. J. C., Christ, A. N., Harliwong, I., Idrisoglu, S., Manning, S., Nourse, C., Nourbakhsh, E., Wani, S., Wilson, P. J., Markham, E., Cloonan, N., Anderson, M. J., Fink, J. L., Holmes, O., Kazakoff, S. H., Leonard, C., Newell, F., Poudel, B., Song, S., Taylor, D., Waddell, N., Wood, S., Xu, Q., Wu, J., Pinese, M., Cowley, M. J., Lee, H. C., Jones, M. D., Nagrial, A. M., Humphris, J., Chantrill, L. A., Chin, V., Steinmann, A. M., Mawson, A., Humphrey, E. S., Colvin, E. K., Chou, A., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Pettitt, J. A., Merrett, N. D., Toon, C., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Jamieson, N. B., Graham, J. S., Niclou, S. P., Bjerkvig, R., Grützmann, R., Aust, D., Hruban, R. H., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Falconi, M., Zamboni, G., Tortora, G., Tempero, M. A., Gill, A. J., Eshleman, J. R., Pilarsky, C., Scarpa, A., Musgrove, E. A., Pearson, J. V., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- The University of Western Australia (AU)
- St John of God Subiaco Hospital (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Centre de Recherche Public de la Santé (LU)
- University of Bergen (NO)
- Technische Universität Dresden (DE)
- Johns Hopkins University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Verona (IT)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Grimmond, Sean M.
- ORCID
- Waddell, Nicola
- Pajic, Marina
- Patch, Ann-Marie
- Chang, David K.
- Kassahn, Karin S.
- Bailey, Peter
- Johns, Amber L.
- Quek, Kelly
- Quinn, Michael C. J.
- Robertson, Alan J.
- Fadlullah, Muhammad Z. H.
- Christ, Angelika N.
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Wilson, Peter J.
- Cloonan, Nicole
- Anderson, Matthew J.
- Fink, J. Lynn
- Holmes, Oliver
- Kazakoff, Stephen H.
- Leonard, Conrad
- Newell, Felicity
- Poudel, Barsha
- Song, Sarah
- Wood, Scott
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Chin, Venessa
- Mawson, Amanda
- Colvin, Emily K.
- Chou, Angela
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Pettitt, Jessica A.
- Merrett, Neil D.
- Toon, Christopher
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Niclou, Simone P.
- Bjerkvig, Rolf
- Grützmann, Robert
- Aust, Daniela
- Hruban, Ralph H.
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Falconi, Massimo
- Zamboni, Giuseppe
- Tortora, Giampaolo
- Tempero, Margaret A.
- Gill, Anthony J.
- Eshleman, James R.
- Pilarsky, Christian
- Scarpa, Aldo
- Pearson, John V.
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2015-02-25
- Volume
- 518
- Issue
- 7540
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4523082
- OpenAlex
- W1987313243
- Cited by
- 2,642
- References
- 57
- Citations by year
- 2026: 118 · 2025: 171 · 2024: 185 · 2023: 234 · 2022: 259 · 2021: 301 · 2020: 292 · 2019: 251 · 2018: 260 · 2017: 242 · 2016: 226 · 2015: 96
- FWCI
- 120.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, cc-by)
- University of Southern Queensland ePrints (University of Southern Queensland) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- American Association for Cancer Research
- Johns Hopkins University
- Royal College of Pathologists of Australasia
- Wellcome Trust (103721/Z/14/Z, 103721)
- Australian Government
- Cancer Research UK (C596/A18076, C29717/A17263, 17263, A18076, A17263)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- University of Glasgow (C596/A18076)
- Australian Cancer Research Foundation
- Cancer Institute NSW (11/REG/1-10, 09/CDF/2-40, 10/CRF/1-01, 10/TPG/1‐04, 06/ECF/1-24, 08/RSA/1-15, 10/CDF/2-26, 06/RSA/1-05, 11/CDF/3-26, 07/CDF/1-28, 07/CDF/1-03, 10/ECF/2-26, 09/RIG/1-02)
- Gastroenterological Society of Australia
- Royal Australasian College of Physicians
- Petre Foundation
- Queensland Government
- R.T. Hall Trust
- Università degli Studi di Verona
- National Institutes of Health (CA62924)
- Medical Research Council
- National Health and Medical Research Council (631701, 535903, 427601)
- Cancer Council NSW (SRP06-01)
- National Cancer Institute (P50CA-62924, P50CA062924, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, mutational landscape, chromosomal rearrangements, copy number variation, structural variants, tumor subtypes, focal amplification, genomic instability, DNA repair deficiency, TP53, SMAD4, CDKN2A, ARID1A, Robo2, KDM6A, PREX2, BRCA1, BRCA2, PALB2, platinum-based chemotherapy, therapeutic biomarkers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Adenocarcinoma, Animals, DNA Mutational Analysis, DNA Repair, Female, Genetic Markers, Genotype, Humans, Mutation, Pancreatic Neoplasms, Platinum, Genome, Human, Point Mutation, Genes, BRCA1, Carcinoma, Pancreatic Ductal, Xenograft Model Antitumor Assays, Genomics, Genes, BRCA2, Genomic Instability, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
